Cardioshock biomarker
Cardiogenic shock is a formidable complication of myocardial infarction, the mortality rate from which in countries with advanced medicine is 50% in patients who managed to be taken to the hospital. Researchers from Catalonia observed a cohort of patients who had undergone cardiogenic shock to calculate the risk of developing this complication of a heart attack. This is the first molecular study of the risk of cardiogenic shock, based on a proteomic meta-analysis, which allowed the discovery of biomarkers to justify their use in decision-making. The discovery has been patented, and work is underway to combine it with immunological methods widely used in clinical diagnostics.
Cardiogenic shock is a possible complication of a massive heart attack, in which the heart suddenly loses the ability to provide the necessary blood flow. Shock does not complicate all cases of a heart attack, but if it is not diagnosed in time and treatment is not started, it leads to death. The discovery of four proteins that can be used as biomarkers is a new tool that, in combination with existing methods, will help to more reliably diagnose the development of shock.
The researchers analyzed more than 2,600 proteins and identified four of them using mass spectrometry and liquid chromatography, which are characteristic of patients with cardiogenic shock and a poor prognosis for life. The integrated quantitative approach was combined with proteomics, as a result, the CS4P biomarker consisting of these four proteins was discovered. It is included in the European Collection of Recommendations (European reference cohort) as a risk assessment tool for heart attack patients. The new biomarker was compared with two existing risk assessment methods, it was confirmed that the new method complements the existing ones, making them much more reliable.
The proteomic aspect of the work provided valuable information about the mechanisms of development of cardiogenic shock and insufficiency of other organs in severe patients. In other words, the four proteins found can be used as a biomarker for other types of seizures.
One of the next steps will be the preparation of CS4P for determination by enzyme immunoassay (ELISA) for a wide clinical distribution of the biomarker.
Article F. Rueda et al. Protein-based cardiogenic shock patient classifier is published in the European Heart Journal.
Aminat Adzhieva, portal "Eternal Youth" http://vechnayamolodost.ru according to the Centre for Genomic Regulation: A new tool that makes it possible to adapt treatment for patients with cardiogenic shock has been developed.